Anti-Mouse CD40 (Clone FGK45) – PE

Pricing & Details

Product No.C2829
Clone
FGK45
Protein
CD40
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
BP50, TNFRSF5
Applications
FC
Prod No.
Size
Price
Avail.
Qty
Add to cart
C2829-25 µg
25 µg
$65.00
In stock
Max:
Min: 1
Step: 1
C2829-100 µg
100 µg
$200.00
In stock
Max:
Min: 1
Step: 1

Antibody Details

Product Details

Reactivity Species
Mouse
Immunogen
Recombinant Mouse CD40 Fusion Protein
Product Concentration
0.2 mg/ml
Formulation
This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This R-PE conjugate is stable when stored at 2-8°C. Do not freeze.
Country of Origin
USA
Excitation Laser
Blue Laser (488 nm) and/or Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this FGK45 antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Clone FGK45 recognizes an epitope on mouse CD40.
Antigen Distribution
CD40 is widely expressed on antigen-presenting cells such as dendritic cells, B cells, macrophages, and monocytes, in addition to non-immune endothelial cells, basal epithelial cells, and a variety of tumors.
Background
CD40 is a 48 kD type I transmembrane glycoprotein that is a member of the TNFR superfamily. CD40, in association with its ligand CD154 (CD40L) - a 39 kD protein, acts as a costimulatory molecule for the activation of B cells, dendritic cells, monocytes, and other antigen presenting cells. CD40 is involved in Ig isotype switching and dendritic cell maturation, as well as the activation, differentiation and proliferation of B cells. CD40 interacts with TNFR2 and is involved in the regulation of signal transduction. CD40 is a potential target for cancer immunotherapy. Blocking the interaction of CD40 with its ligand (CD154) is the sought-after therapeutic objective for preventing and/or improving both autoimmune diseases and transplant rejection. Studies have shown that monoclonal antibodies that block CD154 in human clinical trials resulted in unanticipated vascular complications. Hence, an interest in the therapeutic potential for antagonist mAbs specific for human CD40 is emerging. Antibodies of particular therapeutic interest are those that do not inhibit CD40 signaling via physical competition with CD154. Additionally, the interaction of CD40 and its ligand (CD154) is found to be essential for amyloid-beta-induced microglial activation, thus plays a significant part in Alzheimer disease pathogenesis.

Antigen Details

Protein
Ligand/Receptor
CD154 (CD40L)
PubMed
NCBI Gene Bank ID
Research Area
Cell Biology
.
Costimulatory Molecules
.
Immunology
.
Neuroscience
.
Neuroscience Cell Markers

References & Citations

1. Grewall, I. S. et al. (1996) Science 73:1864 2. Schonbeck, U. et al. (1997) J. Biol. Chem. 272:19569 3. Armitage, R. J. et al. (1993) J. Immunol. 150:3671 4. Pullen, S. S. et al. (1999) Biochemistry 38:10168
Flow Cytometry

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Cookie Policy
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy.